RxDoctor Payments Data

Andrew Geleris, MD

Neurology · Covina, CANPI 1316906225

Payments from drug & device makers

$271in general payments, 2019–2025

Across 16 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$66
  • AbbVie$49
  • Amgen$36
  • Sunovion Pharmaceuticals Inc.$28
  • Novartis$24
  • Lilly USA, LLC$23
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$22683%
  • Education$4517%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.4$66
AbbVie3$49
Amgen2$36
Sunovion Pharmaceuticals Inc.2$28
Novartis1$24
Lilly USA, LLC1$23
Neurocrine Biosciences, Inc.1$20
GSK1$14
Zyla Life Sciences, Inc.1$11

How this compares

$271 in reported general payments places this provider in the 30th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$80,240
Medicare patients
239
Services billed
5,554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5052$550,747
GlatopaGlatiramer Acetate21$46,854
Glatiramer Acetate17$29,765
UbrelvyUbrogepant13$18,607
Nurtec OdtRimegepant Sulfate14$16,326
Emgality PenGalcanezumab-Gnlm17$11,807
Aimovig AutoinjectorErenumab-Aooe15$10,834
Carbidopa-LevodopaCarbidopa/Levodopa297$9,401
Levetiracetam242$8,096
Sumatriptan Succinate148$7,895
Pyridostigmine Bromide65$7,588
Divalproex Sodium ErDivalproex Sodium155$6,624
Carbamazepine76$5,358
Gabapentin158$5,057
FingolimodFingolimod Hcl12$4,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$49$18,60713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,996 neurology providers in California.

Other neurology in Covina

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →